|
1
|
Liu J, Zhang S, Wang Q, Shen H, Zhang M,
Zhang Y, Yan D and Liu M: Seroepidemiology of hepatitis B virus
infection in 2 million men aged 21–49 years in rural China: A
population-based, cross-sectional study. Lancet Infect Dis.
16:80–86. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Liang X, Bi S, Yang W, Wang L, Cui G, Cui
F, Zhang Y, Liu J, Gong X, Chen Y, et al: Reprint of:
Epidemiological serosurvey of Hepatitis B in China-declining HBV
prevalence due to Hepatitis B vaccination. Vaccine. 31 (Suppl
9):J21–J28. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang Y, Zhou H, Zhang L, Zhong Q, Wang Q,
Shen H, Zhang M, Huang Y, Wang A, Nelson K, et al: Prevalence of
chronic hepatitis B and status of HBV care among rural women who
planned to conceive in China. Sci Rep. 7:120902017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Trépo C, Chan HL and Lok A: Hepatitis B
virus infection. Lancet. 384:2053–2063. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lu F, Li T, Liu S and Zhuang H:
Epidemiology and prevention of hepatitis B virus infection in
China. J Viral Hepat. 17 (Suppl 1):S4–S9. 2010. View Article : Google Scholar
|
|
6
|
Biswas A, Panigrahi R, Pal M, Chakraborty
S, Bhattacharya P, Chakrabarti S and Chakravarty R: Shift in the
hepatitis B virus genotype distribution in the last decade among
the HBV carriers from eastern India: Possible effects on the
disease status and HBV epidemiology. J Med Virol. 85:1340–1347.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Moura IF, Lopes EP, Alvarado-Mora MV,
Pinho JR and Carrilho FJ: Phylogenetic analysis and subgenotypic
distribution of the hepatitis B virus in Recife, Brazil. Infect
Genet Evol. 14:195–199. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang SH, Chen PJ and Yeh SH: Gender
disparity in chronic hepatitis B: Mechanisms of sex hormones. J
Gastroenterol Hepatol. 30:1237–1245. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zheng B, Zhu Y, Wang H and Chen L: Gender
disparity in hepatocellular carcinoma (HCC): Multiple underlying
mechanisms. Sci China Life Sci. 60:575–584. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tan Y, Ye Y, Zhou X, Chen L and Wen D: Age
as a predictor of significant fibrosis features in HBeAg-negative
chronic hepatitis B virus infection with persistently normal
alanine aminotransferase. PLoS One. 10:e01234522015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang H, Huo M, Chao J and Liu P:
Application of bayesian approach to cost-effectiveness analysis of
antiviral treatments in chronic Hepatitis B. PLoS One.
11:e01619362016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Everson GT, Shiffman ML, Hoefs JC, Morgan
TR, Sterling RK, Wagner DA, Lauriski S, Curto TM, Stoddard A and
Wright EC; HALT-C Trial Group, : Quantitative liver function tests
improve the prediction of clinical outcomes in chronic hepatitis C:
Results from the Hepatitis C antiviral long-term treatment against
cirrhosis trial. Hepatology. 55:1019–1029. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ghany MG, Lok AS, Everhart JE, Everson GT,
Lee WM, Curto TM, Wright EC, Stoddard AM, Sterling RK, Di Bisceglie
AM, et al: Predicting clinical and histologic outcomes based on
standard laboratory tests in advanced chronic hepatitis C.
Gastroenterology. 138:136–146. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Qi Y, Gao Z, Xu G, Peng B, Liu C, Yan H,
Yao Q, Sun G, Liu Y, Tang D, et al: DNA polymerase kappa is a key
cellular factor for the formation of covalently closed circular DNA
of Hepatitis B virus. PLoS Pathog. 12:e10058932016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang Z, Li A and Xiao X: Risk factors for
intrauterine infection with hepatitis B virus. Int J Gynaecol
Obstet. 125:158–161. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chan H, Tse C, Mo F, Koh J, Wong VW, Wong
GL, Lam Chan S, Yeo W, Sung JJ and Mok TS: High viral load and
hepatitis B virus subgenotype ce are associated with increased risk
of hepatocellular carcinoma. J Clin Oncol. 26:177–182. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mommeja-Marin H, Mondou E, Blum M and
Rousseau F: Serum HBV DNA as a marker of efficacy during therapy
for chronic HBV infection: Analysis and review of the literature.
Hepatology. 37:1309–1319. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sanai FM, Helmy A, Bzeizi KI, Babatin MA,
Al-Qahtani A, Al-Ashgar HA, Al-Mdani AS, Al-Akwaa A, Almutharea S,
Khan MQ, et al: Discriminant value of serum HBV DNA levels as
predictors of liver fibrosis in chronic hepatitis B. J Viral Hepat.
18:e217–e225. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yuen MF, Tanaka Y, Fong DY, Fung J, Wong
DK, Yuen JC, But DY, Chan AO, Wong BC, Mizokami M and Lai CL:
Independent risk factors and predictive score for the development
of hepatocellular carcinoma in chronic hepatitis B. J Hepatol.
50:80–88. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ozaki K, Matsui O, Gabata T, Kobayashi S,
Koda W and Minami T: Confluent hepatic fibrosis in liver cirrhosis:
Possible relation with middle hepatic venous drainage. Jpn J
Radiol. 31:530–537. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shirvani-Dastgerdi E, Winer BY,
Celià-Terrassa T, Kang Y, Tabernero D, Yagmur E, Rodríguez-Frías F,
Gregori J, Luedde T, Trautwein C, et al: Selection of the highly
replicative and partially multidrug resistant rtS78T HBV polymerase
mutation during TDF-ETV combination therapy. J Hepatol. 67:246–254.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xiang Y, Chen P, Xia JR and Zhang LP: A
large-scale analysis study on the clinical and viral
characteristics of hepatitis B infection with concurrence of
hepatitis B surface or E antigens and their corresponding
antibodies. Genet Mol Res. 16:2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen P, Xie Q, Lu X, Yu C, Xu K, Ruan B,
Cao H, Gao H and Li L: Serum HBeAg and HBV DNA levels are not
always proportional and only high levels of HBeAg most likely
correlate with high levels of HBV DNA: A community-based study.
Medicine (Baltimore). 96:e77662017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chinese Society of Hepatology of Chinese
Medical Association, . The Guidelines for the Prevention and
Treatment of Chronic Hepatitis B (2015). Chinese Journal of
experimental and Clinical Infectious Diseases (Electronic Edition).
19:1–18. 2015.
|
|
25
|
Wang SH, Chen PJ and Yeh SH: Gender
disparity in chronic hepatitis B: Mechanisms of sex hormones. J
Gastroenterol Hepatol. 30:1237–1245. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wu DL, Xu GH, Lu SM, Ma BL, Miao NZ, Liu
XB, Feng JH, Liu N, Zeng QL, Hou WK, et al: Age versus clinical
virological characteristics in chronic hepatitis B virus infection:
A case series study in China. Eur J Gastroenterol Hepatol.
24:406–413. 2012.PubMed/NCBI
|
|
27
|
Dong J, Ying J, Qiu X, Lu Y and Zhang M:
Advanced strategies for eliminating the cccDNA of HBV. Dig Dis Sci.
63:7–15. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Samal J, Kandpal M and Vivekanandan P:
HBeAg-induced miR-106b promotes cell growth by targeting the
retinoblastoma gene. Sci Rep. 7:143712017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yu Y, Wan P, Cao Y, Zhang W, Chen J, Tan
L, Wang Y, Sun Z, Zhang Q, Wan Y, et al: Hepatitis B virus e
antigen activates the suppressor of cytokine signaling 2 to repress
interferon action. Sci Rep. 7:17292017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wan DW, Tzimas D, Smith JA, Kim S, Araujo
J, David R, Lobach I and Sarpel U: Risk factors for early-onset and
late-onset hepatocellular carcinoma in Asian immigrants with
hepatitis B in the United States. Am J Gastroenterol.
106:1994–2000. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lee SA, Kim H, Won YS, Seok SH, Na Y, Shin
HB, Inn KS and Kim BJ: Male-specific hepatitis B virus large
surface protein variant W4P potentiates tumorigenicity and induces
gender disparity. Mol Cancer. 14:232015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wong VW and Janssen HL: Can we use HCC
risk scores to individualize surveillance in chronic hepatitis B
infection? J Hepatol. 63:722–732. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Furrer K, Rickenbacher A, Tian Y, Jochum
W, Bittermann AG, Käch A, Humar B, Graf R, Moritz W and Clavien PA:
Serotonin reverts age-related capillarization and failure of
regeneration in the liver through a VEGF-dependent pathway. Proc
Natl Acad Sci USA. 108:2945–2950. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhang C and Cuervo AM: Restoration of
chaperone-mediated autophagy in aging liver improves cellular
maintenance and hepatic function. Nat Med. 14:959–965. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
LE Couteur D, Cogger V, McCuskey R, DE
Cabo R, Smedsrød B, Sorensen KK, Warren A and Fraser R: Age-related
changes in the liver sinusoidal endothelium: A mechanism for
dyslipidemia. Ann NY Acad Sci. 1114:79–87. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Dusséaux M, Masse-Ranson G, Darche S,
Ahodantin J, Li Y, Fiquet O, Beaumont E, Moreau P, Rivière L,
Neuveut C, et al: Viral load affects the immune response to HBV in
mice with humanized immune system and liver. Gastroenterology.
153:1647–1661.e9. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Choi JW, Kim SH, Seo JH, Cho YS, Won SY,
Park BK, Jeon HH, Lee YK and Lee CK: Real world experience of
telbivudine versus entecavir in patients with chronic Hepatitis B,
including long-term outcomes after treatment modification. Yonsei
Med J. 59:383–388. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang ML, Chen EQ, Tao CM, Zhou TY, Liao J,
Zhang DM, Wang J and Tang H: Pronounced decline of serum HBsAg in
chronic hepatitis B patients with long-term effective nucleos(t)ide
analogs therapy. Scand J Gastroenterol. 52:1420–1426. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kang SH, Yim HJ, Kim HR, Kang K, Suh SJ,
Lee HJ, Yoon EL, Kim JH, Seo YS, Yeon JE and Byun KS: Comparison of
lamivudine plus adefovir therapy versus entecavir with or without
adefovir therapy for adefovir-resistant chronic hepatitis B. J Clin
Gastroenterol. 48:889–895. 2014.PubMed/NCBI
|
|
40
|
Marcellin P, Zoulim F, Hézode C, Causse X,
Roche B, Truchi R, Pauwels A, Ouzan D, Dumortier J, Pageaux GP, et
al: Effectiveness and safety of tenofovir disoproxil fumarate in
chronic Hepatitis B: A 3-year, prospective, real-world study in
france. Dig Dis Sci. 61:3072–3083. 2016. View Article : Google Scholar : PubMed/NCBI
|
